Immunogen Shareholders Approve Merger with AbbVie Inc.

Immunogen (IMGN) has released an update to notify the public and investors about the submission of matters to a vote of security holders.

ImmunoGen, Inc. held a virtual special meeting of shareholders on January 31, 2024, where shareholders approved the Merger Agreement with AbbVie Inc. and its subsidiaries, with 208,162,925 votes in favor. Approximately 76% of outstanding shares participated, forming a quorum. However, the non-binding advisory vote on executive compensation related to the merger did not pass, with 120,475,005 votes against. The proposed adjournment to solicit additional votes was unnecessary as the Merger Agreement received sufficient approval. The merger’s completion is pending the satisfaction of other conditions, including antitrust regulations.

For further insights into IMGN corporate activity, check out TipRanks’ Insiders Trading Activity page.

For a comprehensive understanding of the announcement, you can read the full document here.